6-K
Haleon plc (HLN)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2026
Commission File Number: 001-41411
Haleon plc
(Translation of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| Form<br>20-F ☒ | Form<br>40-F ☐ |
|---|
EXHIBIT INDEX
| Exhibit Number | Description |
|---|---|
| 99.1 | 02 July<br>2026 - “Director/PDMR<br>Shareholding” |
99.1
Haleon plc: Director/PDMR Shareholding
2 July 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by a Person Discharging Managerial Responsibilities ("PDMR").
This notification sets out the details of the vesting of a Haleon share award over ordinary shares made to a PDMR in October 2024 under the Haleon Performance Share Plan and the subsequent sale of ordinary shares to meet tax liabilities.
On 30 June 2026, Dawn Allen, Chief Financial Officer, received the vesting of an award of Haleon ordinary shares under the Haleon Performance Share Plan. Vesting included dividends accrued.
The award under the Performance Share Plan was conditional on continued employment and on the satisfaction of the performance conditions over the performance period ended on 31 December 2025 approved by the Remuneration Committee, which (after tax on the gross award) must be retained until the shareholding requirement is met, and in any event for Executive Directors two years after receipt.
Performance targets and levels of achievement are disclosed in the 2025 Annual Report and 20-F. The award is subject to malus and clawback provisions.
| 1 | Details of the issuer or emission allowance market<br>participant | ||
|---|---|---|---|
| a) | Name of the entity | Haleon plc | |
| b) | LEI | 549300PSB3WWEODCUP19 | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Financial Officer | |
| b) | Initial notification /Amendment to prior<br>notifications | Initial Notification | |
| 3 | Details of the person discharging managerial responsibilities /<br>person closely associated ("PCA") | ||
| a) | PDMR/PCA | PDMR | |
| b) | Name | Dawn Allen | |
| 4 | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted | ||
| a) | Description of Instrument | Share | |
| Identification code | GB00BMX86B70 | ||
| b) | Nature of the transaction | Acquisition of Ordinary Shares in respect of the Haleon plc<br>Performance Share Plan (Buyout award). | |
| c) | Currency, Price(s) and Volume(s) | Price(s) | Volume(s) |
| Nil | 283,193.151771 | ||
| d) | Aggregated information | ||
| - Aggregated volume | N/A | ||
| - Price | |||
| e) | Date of the transaction | 30 June 2026 | |
| f) | Place of the transaction | Outside a trading venue | |
| 4 | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted | ||
| a) | Description of Instrument | Share | |
| Identification code | GB00BMX86B70 | ||
| b) | Nature of the transaction | Automatic disposal of Ordinary Shares resulting from Haleon plc<br>Performance Share Plan (Buyout Award) vesting to cover tax<br>liabilities. | |
| c) | Currency, Price(s) and Volume(s) | Price(s) | Volume(s) |
| £3.523867 | 133,300.732432 | ||
| d) | Aggregated information | ||
| - Aggregated volume | N/A | ||
| - Price | |||
| e) | Date of the transaction | 30 June 2026 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| HALEON PLC<br><br><br>(Registrant) | |||
|---|---|---|---|
| Date:<br>July 02, 2026 | By: | /s/<br>Amanda Mellor | |
| Name: | Amanda<br>Mellor | ||
| Title: | Company<br>Secretary |